Akero Therapeutics, Inc. (AKRO)
54.65
0.00 (0.00%)
USD |
NASDAQ |
Dec 11, 16:00
Akero Therapeutics Cash from Investing (Quarterly): 56.78M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Pfizer Inc. | -2.43B |
| Eli Lilly & Co. | -2.983B |
| Bristol Myers Squibb Co. | -1.702B |
| Adaptive Biotechnologies Corp. | 17.28M |
| Johnson & Johnson | -542.00M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -67.17M |
| Cash from Financing (Quarterly) | -34.03M |
| Free Cash Flow | -250.17M |
| Free Cash Flow Per Share (Quarterly) | -0.8191 |
| Free Cash Flow to Equity (Quarterly) | -31.15M |
| Free Cash Flow to Firm (Quarterly) | -66.08M |
| Free Cash Flow Yield | -5.85% |